SCHEMBL880657

SCHEMBL880657

COC(=O)[C@@H]1C[C@H](NC(=O)OC(C)(C)C)CN1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.46
EPHX2 P34913 1/20 0.43
GAA P10253 2/20 0.41
CTSK P43235 2/20 0.40
KDM1A O60341 1/20 0.38
MAOB P27338 1/20 0.38
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CYP2C9 P11712 1/20 0.36
HSD11B1 P28845 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CHEK2 O96017 2/20 0.35
REN P00797 1/20 0.35
EPHX1 P07099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6239705 1.00 BTK (0.46) BTKEPHX2GAACTSKKDM1A
SCHEMBL8830899 1.00 BTK (0.46) BTKEPHX2GAACTSKKDM1A
SCHEMBL28799651 1.00 BTK (0.46) BTKEPHX2GAACTSKKDM1A
SCHEMBL13282809 1.00 BTK (0.46) BTKEPHX2GAACTSKKDM1A
SCHEMBL8543613 1.00 BTK (0.46) BTKEPHX2GAACTSKKDM1A
Hydrochloric Acid SCHEMBL28402193 0.98 BTK (0.44) BTKEPHX2GAACTSKKDM1A
Hydrochloric Acid SCHEMBL4213546 0.98 BTK (0.44) BTKEPHX2GAACTSKKDM1A
Hydrochloric Acid SCHEMBL2318157 0.98 BTK (0.44) BTKEPHX2GAACTSKKDM1A
SCHEMBL27858926 0.88 BTK (0.39) BTKEPHX2GAACTSKKDM1A
SCHEMBL8151905 0.87 BTK (0.43) BTKEPHX2GAACTSKKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466815-B2 Carboxamide compounds and uses thereof INCYTE CORPORATION (US) 2025-11-11 US disclosed
US-20240150326-A1 CARBOXAMIDE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2024-05-09 US disclosed
CN-112292380-B N- (phenyl) -2- (phenyl) pyrimidine-4-carboxamide derivatives and related compounds as HPK1 inhibitors for the treatment of cancer 因赛特公司 2024-04-05 CN disclosed
US-11731958-B2 Carboxamide compounds and uses thereof INCYTE CORPORATION (US) 2023-08-22 US disclosed
US-20230190950-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS CIDARA THERAPEUTICS, INC. 2023-06-22 US disclosed
EP-3755703-B1 N-(PHENYL)-2-(PHENYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HPK1 INHIBITORS FOR TREATING CANCER INCYTE CORP (US) 2022-05-04 EP disclosed
US-20210094934-A1 CARBOXAMIDE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-04-01 US disclosed
CN-112292380-A N- (phenyl) -2- (phenyl) pyrimidine-4-carboxamide derivatives and related compounds as HPK1 inhibitors for the treatment of cancer 因赛特公司 2021-01-29 CN disclosed
US-10800761-B2 Carboxamide compounds and uses thereof INCYTE CORPORATION (US) 2020-10-13 US disclosed
US-8901315-B2 Thienopyrazole derivative having PDE7 inhibitory activity DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-12-02 US disclosed
US-20140073799-A1 THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-03-13 US disclosed
EP-2433943-A1 Thienopyrazole derivatives having PDE7 inhibitory activity Daiichi Sankyo Company, Limited (JP) 2012-03-28 EP disclosed
US-7932250-B2 Thienopyrazole derivative having PDE7 inhibitory activity DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-04-26 US disclosed
US-7932250-B2 Thienopyrazole derivative having PDE7 inhibitory activity DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-04-26 US disclosed
US-20090131413-A1 Thienopyrazole Derivative Having PDE7 Inhibitory Activity ASUBIO PHARMA CO., LTD. (JP) 2009-05-21 US disclosed
US-20090131413-A1 Thienopyrazole Derivative Having PDE7 Inhibitory Activity ASUBIO PHARMA CO., LTD. (JP) 2009-05-21 US disclosed
EP-0646595-B1 Nucleic acid binding oligomers having C-branches for therapy and diagnosis BAYER AG (DE) 1998-11-04 EP disclosed
US-5623049-A FLEXIBLE ANTISENSE AGENTS COMPRISING OLIGONUCEOTIDES HAVING THE (DEOXY)RIBOSE BACKBONE REPLACED BY AN OLIGOPEPTIDE; PROTEASE- AND NUCLEASE-RESISTANT; VIRICIDES; ATTACHED TO CARRIERS ABLE TO PENETRATATE IN CELLS BAYER AKTIENGESELLSCHAFT (DE) 1997-04-22 US disclosed
EP-0646595-A1 Nucleic acid binding oligomers having C-branches for therapy and diagnosis BAYER AG (DE) 1995-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140073799-A1 THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY PDE7A, PDE7B, PDE3B BTK 1602/4885EPHX2 2176/4885GAA 3005/4885
US-10800761-B2 Carboxamide compounds and uses thereof PCK1, PHKG2, PHKG1 BTK 4531/4885EPHX2 2655/4885GAA 691/4885
US-11731958-B2 Carboxamide compounds and uses thereof PCK1, PHKG2, PHKG1 BTK 4531/4885EPHX2 2655/4885GAA 691/4885
US-20230190950-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS FCGR3B, FCGR1A, FCGR2A BTK 72/4885EPHX2 1085/4885GAA 2534/4885
US-20240150326-A1 CARBOXAMIDE COMPOUNDS AND USES THEREOF PCK1, PHKG2, PHKG1 BTK 4531/4885EPHX2 2655/4885GAA 691/4885
US-20090131413-A1 Thienopyrazole Derivative Having PDE7 Inhibitory Activity PDE7A, PDE7B, PDE3B BTK 1602/4885EPHX2 2176/4885GAA 3005/4885
US-20210094934-A1 CARBOXAMIDE COMPOUNDS AND USES THEREOF PCK1, PHKG2, PHKG1 BTK 4531/4885EPHX2 2655/4885GAA 691/4885
US-12466815-B2 Carboxamide compounds and uses thereof PCK1, PHKG2, PHKG1 BTK 4531/4885EPHX2 2655/4885GAA 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.